Final Results of a Large Multi‐National Postmarketing Safety Study Evaluating Use of the Oral Anti‐Diabetic Drug Saxagliptin and Risk of Five Outcomes

Aug-16

AUTHORS : Dr Vincent Lo Re III, Center for Clinical Epidemiology and Biostatistics, 836 Blockley Hall, 423 Guardian Drive, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104-6021, USA – Email: vincentl@mail.med.upenn.edu – Profile: https://www.med.upenn.edu/apps/faculty/index.php/g275/p6951

JOURNAL : Pharmacoepidemiology and Drug Safety

REFERENCE: 25(S3):245-246

DOI : 10.1002/pds.4070

Final Results of a Large Multi‐National Postmarketing Safety Study Evaluating Use of the Oral Anti‐Diabetic Drug Saxagliptin and Risk of Five Outcomes

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study